Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gamma Interferon May Fight Fungal Infections

By Drug Discovery Trends Editor | November 1, 2007

Interferon may be a strong weapon in the battle against fungal infections in immunocompromised patients, according to an article in the November issue of Microbiology Today. Scientists believe gamma interferon, a protein molecule produced by human cells in response to infections, may help to fight fungal infections.

“Immune cells called neutrophils are rapidly recruited to the site of infection and play an essential role in fungal killing,” say Drs. Javier Capilla, Karl Clemons and David Stevens, of Santa Clara Valley Medical Center, Stanford Medical School and the California Institute for Medical Research. “Gamma interferon enhances the mechanisms of these cells to make them more potent killers of fungi.”

Tests on many fungal infections, including blastomycosis, candidosis and aspergillosis have shown that gamma interferon has beneficial effects in terms of the reduction of the fungus in the organs and on animal survival. But according to Dr Stevens, interferon is not the only answer. “Therapy using gamma interferon alone has failed to clear the fungus completely from infected tissues but it has great potential to add to conventional therapy.”

Release date: October 31, 2007

Source: Society for General Microbiology


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE